José Luis Lázaro-Martínez

Prof. José Luis Lázaro-Martínez

Diabetic Foot Unit, Universidad Complutense de Madrid, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
MEMichael Edwin Edmonds
Michael Edwin Edmonds
José Luis Lázaro-MartínezJosé Luis Lázaro-Martínez
José Luis Lázaro-Martínez
JAJesus Manuel Alfayate-García
Jesus Manuel Alfayate-García
JMJacques Martini
Jacques Martini
JPJean-Michel Petit
Jean-Michel Petit
APAlberto Piaggesi
Alberto Piaggesi

11 February 2014 in Diabetes Care
Verified
Journal Article
Open access
José Luis Lázaro-MartínezJosé Luis Lázaro-Martínez
José Luis Lázaro-Martínez
JAJavier Aragón-Sánchez
Javier Aragón-Sánchez
EGEsther García-Morales
Esther García-Morales
OBJECTIVE: No prospective trials have been carried out comparing antibiotic treatment alone with primarily surgical treatment in patients with diabetes and foot osteomyelitis. The aim of the current study was to compare the outcomes of the treatment of diabetic foot osteomyelitis in patients treated exclusively with antibiotics versus patients who underwent conservative surgery, following up the patients for a period of 12 weeks after healing. RESEARCH DESIGN AND METHODS: Between 1 January 2010 and 31 December 2012, a prospective randomized comparative trial (clinical trial reg. no. NCT01137903, clinicaltrials.gov) of patients with diabetes who had received a diagnosis of neuropathic foot ulcers complicated by osteomyelitis was carried out at the Diabetic Foot Unit at the Complutense University of Madrid. Patients were randomized into the following two groups: the antibiotics group (AG) and the surgical group (SG). Antibiotics were given for a period of 90 days in the AG. Patients in the SG received conservative surgery with postoperative antibiotic treatment for 10 days. RESULTS: Eighteen patients (75%) achieved primary healing in the AG, and 19 (86.3%) in the SG (P = 0.33). The median time to healing was 7 weeks (quartile [Q] 1 to Q5, Q3–Q8) in the AG and 6 weeks (Q1–Q3, Q3–Q9) in the SG (P = 0.72). The conditions of four patients from the AG worsened (16.6%), and they underwent surgery. Three patients from the SG required reoperation. No difference was found between the two groups regarding minor amputations (P = 0.336). CONCLUSIONS: Antibiotic therapy and surgical treatment had similar outcomes in terms of healing rates, time to healing, and short-term complications in patients with neuropathic forefoot ulcers complicated by osteomyelitis without ischemia or necrotizing soft tissue infections.

22 August 2008 in Diabetologia
Verified
Journal Article
Closed access
PDF file
JAJavier Aragón-Sánchez
Javier Aragón-Sánchez
JCJ. J. Cabrera-Galván
J. J. Cabrera-Galván
YQY. Quintana-Marrero
Y. Quintana-Marrero
MHM. J. Hernández-Herrero
M. J. Hernández-Herrero
José Luis Lázaro-MartínezJosé Luis Lázaro-Martínez
José Luis Lázaro-Martínez
DAD. G. Armstrong
D. G. Armstrong


1 March 2020 in Journal of Wound Care
Verified
Journal Article
Closed access
CMChristine Murphy
Christine Murphy
LALeanne Atkin
Leanne Atkin
TSTerry Swanson
Terry Swanson
MTMasahiro Tachi
Masahiro Tachi
YTYih Kai Tan
Yih Kai Tan
PWPauline Wilson
Pauline Wilson

Verified
Journal Article
Open access
PDF file
Marco MeloniMarco Meloni
Marco Meloni
VIValentina Izzo
Valentina Izzo
LGLaura Giurato
Laura Giurato
José Luis Lázaro-MartínezJosé Luis Lázaro-Martínez
José Luis Lázaro-Martínez
Luigi UccioliLuigi Uccioli
Luigi Uccioli
This study aims to evaluate clinical and ulcer characteristics as well the outcomes of patients with diabetic foot ulcers (DFUs). The study group was composed of DFUs patients managed by a limb salvage protocol according to guidance. Clinical and ulcers findings were described, and 1-year outcomes defined as limb salvage, healing, healing time, major amputation and death were compared between neuropathic and ischemic DFUs. One thousand, one hundred and ninety-eight subjects were included; 386 (32.2%) neuropathic and 812 (67.8%) ischemic DFUs. Neuropathic patients were younger (69.5 ± 11.5 vs. 74.5 ± 11.5, p < 0.0001) and reported less cases of nephropathy (22.8 vs. 39.6%, p < 0.0001), ischemic heart disease (22.8 vs. 36.9, p = 0.0004), cerebrovascular disease (8.3 vs. 17.2%, p = 0.002), heart failure (10.1 vs. 24.7%, p = 0.0002) and end-stage-renal-disease (ESRD) (5.4 vs. 27%, p = 0.0001) than ischemic patients; they also showed less cases of large (>5 cm2) (10.3 vs. 22.9%, p = 0.0007), infected (40.4 vs. 55.7%, p = 0.0005) and deep to the bone (22.3 vs. 39.2, p = 0.0002) ulcers, as well less multiple ulcerations (21.8 vs. 32.8%, p = 0.006) than patients with ischemic DFUs. The outcomes for neuropathic and ischemic DFUs were limb salvage (98.4 vs. 82.3%, p < 0.0001), healing (97.3 vs. 79.6%, p < 0.0001), healing time (34.9 vs. 35.6 weeks, p = 0.8), major amputation (0.5 vs. 6.6%, p = 0.0001), death (1.1 vs. 11%, p < 0.0001) respectively. Revascularization failure and ESRD were independent predictors of major amputation, while heart failure and number of co-morbidities (≥5) were independent predictors of death. Ischemic DFUs patients showed more severe clinical and ulcers features as well worse outcomes than neuropathic DFUs patients.